Loading...

IRadimed

Nasdaq:IRMD
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IRMD
Nasdaq
$205M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. The last earnings update was 76 days ago. More info.


Add to Portfolio Compare Print
  • IRadimed has significant price volatility in the past 3 months.
IRMD Share Price and Events
7 Day Returns
1.5%
NasdaqCM:IRMD
0.9%
US Medical Equipment
-1.2%
US Market
1 Year Returns
-17.2%
NasdaqCM:IRMD
14.6%
US Medical Equipment
3.3%
US Market
IRMD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
IRadimed (IRMD) 1.5% -13.2% -34.4% -17.2% -6.8% 96.7%
US Medical Equipment 0.9% 1% 12% 14.6% 64% 104.1%
US Market -1.2% 0.8% 0.9% 3.3% 35.9% 41.7%
1 Year Return vs Industry and Market
  • IRMD underperformed the Medical Equipment industry which returned 14.6% over the past year.
  • IRMD underperformed the Market in United States of America which returned 3.3% over the past year.
Price Volatility
IRMD
Industry
5yr Volatility vs Market

IRMD Value

 Is IRadimed undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of IRadimed to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for IRadimed.

NasdaqCM:IRMD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:IRMD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.87 (1 + (1- 21%) (1.52%))
0.92
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.92
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.92 * 5.96%)
8.21%

Discounted Cash Flow Calculation for NasdaqCM:IRMD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for IRadimed is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqCM:IRMD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.21%)
2020 5.53 Est @ -1.85% 5.11
2021 5.50 Est @ -0.48% 4.70
2022 5.53 Est @ 0.48% 4.36
2023 5.59 Est @ 1.16% 4.08
2024 5.68 Est @ 1.63% 3.83
2025 5.80 Est @ 1.96% 3.61
2026 5.92 Est @ 2.19% 3.41
2027 6.06 Est @ 2.35% 3.22
2028 6.21 Est @ 2.47% 3.05
2029 6.37 Est @ 2.55% 2.89
Present value of next 10 years cash flows $38.27
NasdaqCM:IRMD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $6.37 × (1 + 2.73%) ÷ (8.21% – 2.73%)
$119.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $119.39 ÷ (1 + 8.21%)10
$54.23
NasdaqCM:IRMD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $38.27 + $54.23
$92.51
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $92.51 / 11.16
$8.29
NasdaqCM:IRMD Discount to Share Price
Calculation Result
Value per share (USD) From above. $8.29
Current discount Discount to share price of $18.39
= -1 x ($18.39 - $8.29) / $8.29
-121.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of IRadimed is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for IRadimed's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are IRadimed's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:IRMD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.67
NasdaqCM:IRMD Share Price ** NasdaqCM (2019-07-22) in USD $18.39
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 40.94x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of IRadimed.

NasdaqCM:IRMD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:IRMD Share Price ÷ EPS (both in USD)

= 18.39 ÷ 0.67

27.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IRadimed is good value based on earnings compared to the US Medical Equipment industry average.
  • IRadimed is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does IRadimed's expected growth come at a high price?
Raw Data
NasdaqCM:IRMD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 27.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
30.9%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 54 Publicly-Listed Medical Equipment Companies 2.38x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

NasdaqCM:IRMD PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 27.34x ÷ 30.9%

0.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IRadimed is good value based on expected growth next year.
Price based on value of assets
What value do investors place on IRadimed's assets?
Raw Data
NasdaqCM:IRMD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.01
NasdaqCM:IRMD Share Price * NasdaqCM (2019-07-22) in USD $18.39
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.34x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.79x
NasdaqCM:IRMD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:IRMD Share Price ÷ Book Value per Share (both in USD)

= 18.39 ÷ 4.01

4.59x

* Primary Listing of IRadimed.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IRadimed is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess IRadimed's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. IRadimed has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IRMD Future Performance

 How is IRadimed expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
30.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is IRadimed expected to grow at an attractive rate?
  • IRadimed's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • IRadimed's earnings growth is expected to exceed the United States of America market average.
  • IRadimed's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:IRMD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:IRMD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 30.9%
NasdaqCM:IRMD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 22.8%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.5%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:IRMD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:IRMD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 60 16 1
2020-12-31 49 11 1
2019-12-31 39 8 1
NasdaqCM:IRMD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 32 6 7
2018-12-31 30 7 6
2018-09-30 29 5 5
2018-06-30 27 6 3
2018-03-31 25 5 2
2017-12-31 23 3 0
2017-09-30 22 4 1
2017-06-30 24 6 3
2017-03-31 29 7 5
2016-12-31 32 9 7
2016-09-30 35 10 8
2016-06-30 35 9 9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • IRadimed's earnings are expected to grow significantly at over 20% yearly.
  • IRadimed's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:IRMD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from IRadimed Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:IRMD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 1.25 1.25 1.25 1.00
2020-12-31 0.89 0.89 0.89 1.00
2019-12-31 0.64 0.64 0.64 1.00
NasdaqCM:IRMD Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.67
2018-12-31 0.59
2018-09-30 0.45
2018-06-30 0.24
2018-03-31 0.15
2017-12-31 0.05
2017-09-30 0.14
2017-06-30 0.26
2017-03-31 0.44
2016-12-31 0.67
2016-09-30 0.78
2016-06-30 0.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if IRadimed will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess IRadimed's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
IRadimed has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IRMD Past Performance

  How has IRadimed performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare IRadimed's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • IRadimed's year on year earnings growth rate has been positive over the past 5 years.
  • IRadimed's 1-year earnings growth exceeds its 5-year average (364.2% vs 6%)
  • IRadimed's earnings growth has exceeded the US Medical Equipment industry average in the past year (364.2% vs 31.9%).
Earnings and Revenue History
IRadimed's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from IRadimed Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:IRMD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 31.77 7.31 16.29 1.48
2018-12-31 30.44 6.30 15.71 1.52
2018-09-30 28.80 4.78 15.23 1.50
2018-06-30 26.88 2.57 15.06 1.51
2018-03-31 25.03 1.57 14.98 1.56
2017-12-31 23.08 0.50 14.50 1.72
2017-09-30 22.37 1.46 13.61 1.74
2017-06-30 24.35 2.83 13.02 1.81
2017-03-31 28.69 4.70 14.00 1.65
2016-12-31 32.50 7.21 14.07 1.35
2016-09-30 34.94 8.48 14.70 1.48
2016-06-30 35.46 8.79 14.37 1.54
2016-03-31 33.20 8.32 12.96 1.66
2015-12-31 31.23 7.53 12.42 1.76
2015-09-30 26.18 5.40 11.10 1.58
2015-06-30 21.80 3.77 10.36 1.36
2015-03-31 18.89 3.01 9.26 1.19
2014-12-31 15.45 2.05 8.11 1.07
2014-09-30 15.37 2.25 7.43 1.10
2014-06-30 14.03 2.28 6.44 1.09
2014-03-31 12.11 1.82 5.47 1.07
2013-12-31 11.18 1.94 4.69 1.01
2012-12-31 7.69 0.97 3.48 0.65

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • IRadimed has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • IRadimed used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • IRadimed's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess IRadimed's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
IRadimed has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IRMD Health

 How is IRadimed's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up IRadimed's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • IRadimed is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • IRadimed's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of IRadimed's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • IRadimed has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from IRadimed Company Filings, last reported 3 months ago.

NasdaqCM:IRMD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 44.65 0.00 35.43
2018-12-31 41.95 0.00 34.38
2018-09-30 40.09 0.00 31.19
2018-06-30 36.17 0.00 29.50
2018-03-31 34.24 0.00 27.92
2017-12-31 32.93 0.00 26.34
2017-09-30 32.14 0.00 25.21
2017-06-30 31.30 0.00 23.82
2017-03-31 32.03 0.00 25.25
2016-12-31 31.89 0.00 25.68
2016-09-30 30.64 0.00 23.82
2016-06-30 28.47 0.00 20.15
2016-03-31 29.25 0.00 23.55
2015-12-31 31.93 0.00 26.97
2015-09-30 28.11 0.00 23.42
2015-06-30 25.09 0.00 20.33
2015-03-31 22.97 0.00 18.70
2014-12-31 20.89 0.00 17.37
2014-09-30 20.15 0.00 18.11
2014-06-30 7.30 0.00 4.52
2014-03-31 6.11 0.00 3.16
2013-12-31 5.42 0.01 2.71
2012-12-31 3.22 0.52 1.95
  • IRadimed has no debt.
  • IRadimed had no debt 5 years ago.
  • IRadimed has no debt, it does not need to be covered by operating cash flow.
  • IRadimed has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess IRadimed's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. IRadimed has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IRMD Dividends

 What is IRadimed's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from IRadimed dividends.
If you bought $2,000 of IRadimed shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate IRadimed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate IRadimed's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:IRMD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:IRMD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as IRadimed has not reported any payouts.
  • Unable to verify if IRadimed's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of IRadimed's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as IRadimed has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess IRadimed's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can IRadimed afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. IRadimed has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IRMD Management

 What is the CEO of IRadimed's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Roger Susi
COMPENSATION $494,580
AGE 66
TENURE AS CEO 15.5 years
CEO Bio

Mr. Roger E. Susi founded IRadimed Corporation in 2004 and serves as its Chief Executive Officer and President since 2004 and has been its Chairman of the Board since June 10, 2016. Mr. Susi founded Invivo Research Inc., a wholly owned subsidiary of Invivo Corporation and served as its President from 1979 to November 1998. He serves as the Chairman of Invivo Corporation (formerly, Invivo Research Inc). Mr. Susi served as a director of Invivo Corporation from 1998 to 2000. He serves as a Director of IRadimed Corporation. He has over 35 years of management experience in the medical device industry. Mr. Susi is a biomedical engineer and received a B.S. in Biomedical Engineering from Case Western Reserve University in 1977.

CEO Compensation
  • Roger's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Roger's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the IRadimed management team in years:

7.5
Average Tenure
64
Average Age
  • The average tenure for the IRadimed management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Roger Susi

TITLE
Founder
COMPENSATION
$495K
AGE
66
TENURE
15.5 yrs

Chris Scott

TITLE
CFO & Secretary
COMPENSATION
$508K
AGE
49
TENURE
5.6 yrs

John McCreery

TITLE
Chief Operating Officer
COMPENSATION
$437K
AGE
64
TENURE
2.3 yrs

Brent Johnson

TITLE
Executive Vice President of Worldwide Sales & Marketing
COMPENSATION
$454K
AGE
60
TENURE
7.5 yrs

Louis Waldman

TITLE
Controller
AGE
64
TENURE
14.5 yrs
Board of Directors Tenure

Average tenure and age of the IRadimed board of directors in years:

3.2
Average Tenure
66
Average Age
  • The tenure for the IRadimed board of directors is about average.
Board of Directors

Roger Susi

TITLE
Founder
COMPENSATION
$495K
AGE
66
TENURE
3.1 yrs

Monty Allen

TITLE
Independent Director
COMPENSATION
$155K
AGE
66
TENURE
5.5 yrs

Anthony Vuoto

TITLE
Independent Director
COMPENSATION
$153K
AGE
68
TENURE
3.3 yrs

Jim Hawkins

TITLE
Director
COMPENSATION
$36K
AGE
63
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
06. Mar 19 Sell Steve Nardi Individual 04. Mar 19 04. Mar 19 -1,418 $26.07 $-36,961
17. Sep 18 Sell Francis Casey Individual 13. Sep 18 14. Sep 18 -55,000 $30.51 $-1,611,404
10. Aug 18 Sell Monty Allen Individual 09. Aug 18 09. Aug 18 -4,347 $27.04 $-117,526
10. Aug 18 Sell Louis Waldman Individual 08. Aug 18 08. Aug 18 -35,000 $26.06 $-911,925
10. Aug 18 Sell John McCreery Individual 08. Aug 18 09. Aug 18 -7,000 $27.55 $-191,113
03. Aug 18 Sell Steve Nardi Individual 02. Aug 18 02. Aug 18 -786 $23.80 $-18,706
X
Management checks
We assess IRadimed's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. IRadimed has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IRMD News

Simply Wall St News

Does IRadimed Corporation's (NASDAQ:IRMD) P/E Ratio Signal A Buying Opportunity?

See our latest analysis for IRadimed How Do I Calculate A Price To Earnings Ratio? … The formula for price to earnings is: Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS) Or for IRadimed: P/E of 26.85 = $18.06 ÷ $0.67 (Based on the trailing twelve months to March 2019.) Is A High Price-to-Earnings Ratio Good? … The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings.

Simply Wall St -

Should You Consider IRadimed Corporation (NASDAQ:IRMD)?

Flawless balance sheet with high growth potential Investors in search for stocks with room to flourish should look no further than IRMD, with its expected earnings growth of 31%. … Over the past few years, IRMD has more than doubled its earnings, with its most recent figure exceeding its annual average over the past five years. … Dividend Income vs Capital Gains: Does IRMD return gains to shareholders through reinvesting in itself and growing earnings, or redistribute a decent portion of earnings as dividends?

Simply Wall St -

What Does IRadimed Corporation's (NASDAQ:IRMD) Share Price Indicate?

IRadimed Corporation (NASDAQ:IRMD), which is in the medical equipment business, and is based in United States, saw a decent share price growth in the teens level on the NASDAQCM over the last few months. … What’s more interesting is that, IRadimed’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. … Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations.

Simply Wall St -

Should You Be Worried About Insider Transactions At IRadimed Corporation (NASDAQ:IRMD)?

So shareholders might well want to know whether insiders have been buying or selling shares in IRadimed Corporation (NASDAQ:IRMD). … IRadimed Insiders Are Selling The Stock We have seen a bit of insider selling at IRadimed, over the last three months. … It's great to see high levels of insider ownership, but looking back at the last year, we don't gain confidence from the IRadimed insiders selling.

Simply Wall St -

Does IRadimed Corporation's (NASDAQ:IRMD) Stock Price Account For Its Growth?

IRadimed Corporation (NASDAQ:IRMD) is considered a high growth stock. … IRadimed is poised for extremely high earnings growth in the near future. … IRadimed is trading at price-to-earnings (PE) ratio of 34.3x, this tells us the stock is overvalued compared to the US market average ratio of 17.89x , and undervalued based on its latest annual earnings update compared to the Medical Equipment average of 38.66x.

Simply Wall St -

A Closer Look At IRadimed Corporation's (NASDAQ:IRMD) Impressive ROE

This article is for those who would like to learn about Return On Equity (ROE). … Another way to think of that is that for every $1 worth of equity in the company, it was able to earn $0.16. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Are IRadimed Corporation’s (NASDAQ:IRMD) High Returns Really That Great?

Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. … What is Return On Capital Employed (ROCE)? … The formula for calculating the return on capital employed is:

Simply Wall St -

What Kind Of Shareholders Own IRadimed Corporation (NASDAQ:IRMD)?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … IRadimed is a smaller company with a market capitalization of US$306m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

How Should Investors Feel About IRadimed Corporation's (NASDAQ:IRMD) CEO Pay?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Roger Susi's Compensation Compare With Similar Sized Companies. … Our data indicates that IRadimed Corporation is worth US$307m, and total annual CEO compensation is US$474k.

Simply Wall St -

What Do Analysts Think About The Future Of IRadimed Corporation's (NASDAQ:IRMD)?

In December 2018, IRadimed Corporation (NASDAQ:IRMD) announced its latest earnings update, whicha … revealed

Simply Wall St -

IRMD Company Info

Description

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

Details
Name: IRadimed Corporation
IRMD
Exchange: NasdaqCM
Founded: 1992
$205,181,312
11,157,222
Website: http://www.iradimed.com
Address: IRadimed Corporation
1025 Willa Springs Drive,
Winter Springs,
Florida, 32708,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM IRMD Common Shares Nasdaq Capital Market US USD 16. Jul 2014
DB 46K Common Shares Deutsche Boerse AG DE EUR 16. Jul 2014
BST 46K Common Shares Boerse-Stuttgart DE EUR 16. Jul 2014
Number of employees
Current staff
Staff numbers
95
IRadimed employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/23 00:52
End of day share price update: 2019/07/22 00:00
Last estimates confirmation: 2019/05/17
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.